What SigutLabs does

SigutLabs s.r.o. is a Prague-based contract research organization (CRO) specializing in organic, bioorganic, and medicinal chemistry. The firm was founded around 2010 by CEO Krystof Sigut (rebranded from Santiago Labs in September 2024) and operates from a laboratory at Radiova 1285/7 in Prague, Czech Republic, with a billing entity registered at Minická 189. SigutLabs is wholly founder-owned, with no disclosed institutional investors, parent company, or subsidiaries, and runs an all-PhD technical team led by Head of Research Petr Slavik.

The company delivers three core service lines: (1) Custom Synthesis of previously reported molecules via known procedures, (2) Contract Research developing novel synthetic routes to undescribed compounds, and (3) Scale-Up services transitioning laboratory quantities to industrial batches. Specialized chemistry domains include ADC linker-payload systems (including novel cysteine-reactive warheads such as 2-methyl(sulfonyl)pyrimidine), nucleoside and nucleotide chemistry, peptide and click-chemistry, organometallic chemistry, and lincosamide antibiotic development. A joint international patent application (WO2018161979) is pending with the Czech Academy of Sciences on lincosamide derivatives as antimicrobial agents. Operational capabilities include an in-house purification technology demonstrated at 350 kg vitamin K2 oil scale and reported 95% on-time shipment within two days.

Revenue is generated through two contract models — Fee-for-Service (FFS) for projects with literature precedent, priced per delivery and paid only on successful completion, and Full-Time Equivalent (FTE) for novel research with monthly billing and weekly progress reporting — plus a transactional e-commerce channel at sigutlabs.com/eshop/ listing 199+ catalog research chemicals (nucleoside analogues, ADC reagents, specialty compounds) priced €100-€9,000, and listings on Scientist.com and Science Exchange marketplaces. Customers span pharmaceutical companies, biotechnology firms, and academic research institutions globally, with named partners including Scripps Research Institute, Sanford Burnham Prebys, NIH/NIEHS, ETH Zurich, Johns Hopkins, Karolinska Institutet, Université Laval, Charles University, and an unnamed California biotech startup whose ADC candidate advanced to Phase 1. Non-dilutive funding flows from EU and Czech government programmes (Technology Agency of the Czech Republic TREND, Czech Rise Up 3.0, Ministry of Industry and Trade, National Recovery Plan Creative Vouchers).

Name

SigutLabs

Legal name

SigutLabs s.r.o.

Website

https://sigutlabs.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

1–10 employees

Short description

SigutLabs is a Prague-based contract research organization providing custom synthesis, novel-route contract research, and scale-up services in organic, bioorganic, and medicinal chemistry — including ADC linkers and nucleoside chemistry — to pharmaceutical companies, biotech firms, and academic research institutions globally via FFS, FTE, and e-shop channels.

Ownership category

akta.pro rank

Product category

Contract Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Chemical Manufacturing (325)

SIC

Services-Commercial Physical & Biological Research (8731), Industrial Organic Chemicals (2860)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industries

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Chiral / Asymmetric Synthesis & Complex Chemistry Services (HLAGAHAE)

Keywords

• Contract research services
• Custom synthesis chemistry
• Scale-up chemistry services
• Medicinal chemistry CRO
• Nucleoside nucleotide synthesis

Headquarters

HQ city

Prague

HQ country

Czechia

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Custom Synthesis Services: Synthesis of previously reported molecules using described synthetic procedures for research purposes
2. Contract Research Services: Developing novel synthetic routes for undescribed compounds in organic, bioorganic, and medicinal chemistry under FFS or FTE contract models
3. Scale-Up Services: Lab-to-industry scaling services for clients requiring larger quantities of compounds
4. Product Sales (E-shop): Sale of research chemicals, nucleoside/nucleotide analogues, and reagents through online storefront with prices ranging from €100 to €9000

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

SigutLabs is a contract research organization (CRO) providing custom synthesis, contract research, and lab-to-industry scale-up services in organic, bioorganic, and medicinal chemistry for pharmaceutical and biotechnology clients. The company creates custom molecules, develops novel synthetic routes for undescribed compounds, and scales laboratory chemistry to industrial production. It also sells research chemicals (nucleoside/nucleotide analogues, reagents) through its online e-shop.

Product overview

SigutLabs is a contract research organization (CRO) providing specialized chemistry services to pharmaceutical and biotechnology companies. The company operates as a single unified service platform offering three core service lines: Custom Synthesis for producing known molecules via reported methods, Contract Research for developing novel synthetic routes to undescribed compounds, and Scale-Up services for transitioning from laboratory to industrial production. Additionally, the company maintains an E-shop catalog of research chemicals including nucleoside/nucleotide analogues, ADC linker-payload systems, and modified compounds. The services are delivered by an all-PhD team based in Prague, Czech Republic, with global delivery capabilities including clients in Silicon Valley.

Differentiator

Problem solved

Functional benefit

Products and services

• Custom Synthesis Service for creating custom molecules via known synthesis methods using reported synthetic procedures for previously described compounds. Targeted at pharmaceutical, biotechnology, and academic research clients needing access to specific known compounds.
• Contract Research Service for developing novel synthetic routes to provide undescribed compounds in organic, bioorganic, and medicinal chemistry. Targeted at clients requiring new chemistry approaches where no literature precedent exists, with engagement under Fee-for-Service or Full-Time Equivalent contract models.
• Scale-Up Service enabling lab-to-industry scaling with advanced instruments, helping clients transition from laboratory scales to industrial-scale production. Targeted at clients requiring larger quantities of compounds for preclinical or clinical programs (demonstrated with 30+ g lincomycin derivative scale-up).
• Nucleoside/Nucleotide Analogues (E-shop Catalog) Catalog of research chemicals including nucleoside triphosphates, modified nucleotides, and reagents for antiviral and anticancer research applications. Sold via the SigutLabs e-shop and on scientific marketplace platforms (Scientist.com, Science Exchange).
• Large-Scale Purification Services Industrial-scale purification processes for temperature-sensitive and UV-sensitive compounds. Demonstrated through a 350 kg vitamin K2 oil purification completed in 14 days, reducing the client's process from days to hours. Targeted at manufacturers requiring purification of large crude batches.

Quantifiable outcome

• 95% of shipments delivered within 2 days
• +3 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• The Scripps Research InstitutecoreStrategic or Co-development PartnerResearch partnership for custom synthesis and contract research services supporting Scripps research programs.
• Sanford Burnham PrebyscoreStrategic or Co-development PartnerCollaborative research partnership supporting这家 independent medical research institute's drug discovery efforts.
• National Institute of Environmental Health SciencescoreStrategic or Co-development PartnerPartnership supporting NIEHS research programs with custom synthesis services.
• ETH ZurichcoreStrategic or Co-development PartnerCollaborative research with one of Europe's leading technical universities.
• Institute of Organic Chemistry and Biochemistry of the Czech Academy of SciencescoreStrategic or Co-development PartnerOngoing collaboration including joint patent application WO2018161979 for lincosamide antibiotics development.
• Johns Hopkins UniversitycoreStrategic or Co-development PartnerResearch collaboration providing custom-synthesized compounds for academic research programs.
• Université LavalcoreStrategic or Co-development PartnerPartnership with Canadian research university for custom synthesis services.
• University of MinnesotacoreStrategic or Co-development PartnerResearch collaboration supporting university's pharmaceutical sciences research.
• University of TurkuminorStrategic or Co-development PartnerResearch partnership with Finnish university.
• University of Chemistry and Technology PragueminorStrategic or Co-development PartnerPartnership with Czech technical university for research collaboration.
• Brno University of TechnologyminorStrategic or Co-development PartnerPartnership with Czech technical university.
• Uniwersytet Gdański (University of Gdańsk)minorStrategic or Co-development PartnerPartnership with Polish research university.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Enamine: Ukraine-headquartered specialty chemistry CRO offering custom synthesis, building blocks, and screening libraries with an all-PhD-level scientific staff. Closely comparable niche focus on novel synthesis routes and catalog chemical supply, with a similar cost-efficient Eastern European operating model.
• ChemPartner: Asia-headquartered CRO providing discovery chemistry, custom synthesis, and process R&D services to global pharma and biotech. Comparable on FTE/FFS contract chemistry model and target customer base of pharma and biotech clients.
• Bide Pharmatech: Specialty CRO focused on custom synthesis, building blocks, and medicinal chemistry services, with a strong online catalog of research chemicals. Directly comparable business model combining FFS custom synthesis with e-commerce reagent sales, similar in scale and customer mix.
• Cayman Chemical: Research chemical supplier and contract synthesis provider with deep catalog of nucleosides, nucleotides, lipids, and biochemical reagents. Comparable on e-shop product strategy and custom synthesis for research institutes and biotechs, though Cayman is much larger and more catalog-driven.
• Combi-Blocks: US-based provider of screening compounds, building blocks, and custom synthesis services with a large e-commerce catalog. Comparable in combining catalog reagent sales with custom synthesis and serving medicinal chemistry research customers across pharma and academia.

Broad incumbents

• Eurofins Discovery: Large CRO network offering medicinal chemistry, custom synthesis, and ADME/tox services. Comparable on contract research and custom synthesis offerings but operating at parent-Eurofins scale with integrated in vitro and in vivo capabilities.
• Pharmaron: Full-service CRO/CDMO offering discovery chemistry, custom synthesis, process R&D, and scale-up. Comparable on core CRO chemistry services but with substantially broader integrated capabilities, multiple global sites, and large pharma clients.
• Charles River Laboratories: Global, full-service CRO spanning discovery chemistry, safety assessment, and manufacturing. Comparable in offering custom synthesis and contract research services to pharma and biotech, though Charles River operates at vastly larger scale with publicly disclosed financials.
• Syngene International: India-based integrated CRO/CDMO offering medicinal chemistry, custom synthesis, and development/manufacturing services. Comparable on contract research and chemistry services for global pharma, though with much broader scale and service scope.
• WuXi AppTec (WuXi STA): Global CRO/CDMO with extensive custom synthesis, medicinal chemistry, and ADC linker/payload capabilities. Directly comparable on contract research, custom synthesis, and scale-up services, but operating at vastly larger scale and offering integrated discovery-to-manufacturing workflows that SigutLabs does not.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/sigutlabs

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SigutLabs